Published in Eur J Gastroenterol Hepatol on January 01, 2000
Metformin-induced mixed hepatocellular and cholestatic hepatic injury: case report and literature review. Int J Gen Med (2013) 0.83
Non-alcoholic fatty liver disease and diabetes. Metabolism (2016) 0.82
Gliclazide-induced acute hepatitis with hypersensitivity features. Dig Dis Sci (2002) 0.76
Glipizide treatment with short-term alcohol abuse resulting in subfulminant hepatic failure. Virchows Arch (2003) 0.75
Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med (1981) 3.17
Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBe positive carriers of hepatitis B virus. Hepatology (1983) 2.36
Detection of hepatitis B virus DNA directly in human serum by a simplified molecular hybridization test: comparison to HBeAg/anti-HBe status in HBsAg carriers. Hepatology (1983) 2.10
Multiple systems organ failure from organophosphate poisoning. J Toxicol Clin Toxicol (1995) 1.79
The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol (2001) 1.39
Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology (2001) 1.38
Old and emerging therapies in chronic hepatitis C: an update. J Viral Hepat (2008) 1.22
Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther (2001) 1.20
Hepatitis-associated antigen in chronic liver disease. Lancet (1970) 1.19
Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative Research. Eur J Gastroenterol Hepatol (2000) 1.16
Malignant gastrointestinal melanomas of unknown origin: should it be considered primary? World J Gastroenterol (2007) 1.14
Diagnosis and management of pre-core mutant chronic hepatitis B. J Viral Hepat (2001) 1.10
Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut (2003) 1.08
Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. J Viral Hepat (2006) 1.07
Over-expression of p53 nuclear oncoprotein in colorectal adenomas. Int J Cancer (1992) 1.07
Changes in epidemiological patterns of HCV infection and their impact on liver disease over the last 20 years in Greece. J Viral Hepat (2005) 1.06
Liver disease activity and hepatitis B virus replication in chronic delta antigen-positive hepatitis B virus carriers. Hepatology (1985) 1.05
Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology (1995) 1.05
Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection. Gut (2007) 1.05
Desmoid tumor presenting as intra-abdominal abscess. Dig Dis Sci (2006) 1.04
Interrupted replication of hepatitis B virus in liver tissue of HBsAg carriers with hepatocellular carcinoma. Virology (1988) 1.02
Alpha-chain disease with clinical, immunological, and histological recovery. Br Med J (1974) 1.02
Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients. J Viral Hepat (1998) 1.02
Cholestatic jaundice as a paraneoplastic manifestation of renal cell carcinoma. Eur J Gastroenterol Hepatol (1997) 1.00
Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Ann Oncol (2006) 1.00
Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: a 4-year follow-up of 211 patients. Hepatology (1997) 0.96
Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J Viral Hepat (2008) 0.95
Serum hepcidin levels are related to the severity of liver histological lesions in chronic hepatitis C. J Viral Hepat (2010) 0.94
Review article: current management of chronic hepatitis B. Aliment Pharmacol Ther (2004) 0.94
Fulminant hepatic failure as a presenting paraneoplastic manifestation of Hodgkin's disease. Eur J Gastroenterol Hepatol (1999) 0.91
Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. J Viral Hepat (2009) 0.91
Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin. J Viral Hepat (2013) 0.90
Reversal of liver failure in sickle cell vaso-occlusive crisis. Am J Med Sci (1996) 0.88
Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2007) 0.87
Immune thrombocytopenia and alpha-interferon therapy. J Hepatol (1996) 0.86
Hepatocellular carcinoma and type B hepatitis. Clin Gastroenterol (1980) 0.86
Prolonged cholestatic jaundice after endoscopic retrograde cholangiography. Hepatogastroenterology (1997) 0.85
Hepatitis G virus infection: clinical characteristics and response to interferon. J Viral Hepat (1997) 0.85
Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C. Dig Liver Dis (2007) 0.84
Cellular immune responses in hepatitis B virus e antigen negative chronic hepatitis B. J Viral Hepat (2008) 0.83
A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther (2006) 0.83
Chronic hepatitis B. Prog Liver Dis (1990) 0.83
Nonparenteral transmission of viral hepatitis in Greece. Am J Med Sci (1977) 0.82
Chronic viral hepatitis. Clin Gastroenterol (1974) 0.82
Recombinant interferon-alpha therapy for acute hepatitis B: a randomized, double-blind, placebo-controlled trial. J Viral Hepat (1997) 0.82
Recurrent hepatic sarcoidosis following liver transplantation. Transplant Proc (1997) 0.81
Absence of the negative strand of GBV-C/HGV RNA from the liver. J Hepatol (1999) 0.81
Does delta infection play a part in the pathogenesis of hepatitis B virus related hepatocellular carcinoma? Br Med J (Clin Res Ed) (1984) 0.80
High levels of HCV core+1 antibodies in HCV patients with hepatocellular carcinoma. J Gen Virol (2011) 0.79
Emergence and selection of HBV variants in an anti-HBe positive patient persistently infected with quasi-species. J Hepatol (1997) 0.79
Combined hepatocellular-cholangiocarcinoma presented with massive pulmonary embolism. Hepatogastroenterology (2001) 0.78
Splenic infarct as a late complication of liver transplantation. Eur J Gastroenterol Hepatol (1998) 0.78
Induction interferon therapy in naïve patients with chronic hepatitis C: increased end-of-treatment virological responses but absence of long-term benefit. Aliment Pharmacol Ther (2001) 0.77
Whole genome analysis of hepatitis B virus from four cases of fulminant hepatitis: genetic variability and its potential role in disease pathogenicity. J Viral Hepat (1996) 0.77
Measurement of hepatitis B viral DNA in serum by solution hybridization and comparison with the dot-blot hybridization technique. Hepatogastroenterology (1991) 0.77
Emergence of the long form of hepatitis delta virus antigen in transfected cells after intrahepatic transfection and during natural infection. Prog Clin Biol Res (1993) 0.77
Endemic hepatitis delta virus infection in a Greek community. Prog Clin Biol Res (1987) 0.77
Core variability does not affect response to interferon alpha in HBeAg negative chronic hepatitis B. J Hepatol (1998) 0.76
Post-infantile giant cell hepatitis associated with autoimmune hepatitis and polyarteritis nodosa. Scand J Gastroenterol (2002) 0.76
Sex hormonal preparations and the liver. Eur J Contracept Reprod Health Care (1998) 0.76
The usefulness of transient elastography in the assessment of patients with HBeAg-negative chronic hepatitis B virus infection. J Viral Hepat (2013) 0.76
Molecular pathophysiology of persistent hepatitis B virus infection in relation to chronic liver disease and primary hepatocellular carcinoma. Monogr Pathol (1987) 0.76
Laparoscopic fenestration of multiple giant biliary mucinous cystadenomas of the liver. World J Gastroenterol (2008) 0.76
Letter: Hepatitis-B core antigen and antibody in primary liver cancer. Lancet (1975) 0.76
Sweat gland carcinoma in a patient with sarcoidosis and primary biliary cirrhosis. Dermatology (1994) 0.75
Sclerosing lymphocytic lobulitis in the male breast. J Clin Pathol (1996) 0.75
Limitations of retrospective IL28B polymorphisms and IP-10 real life studies in hepatitis C. Aliment Pharmacol Ther (2011) 0.75
Decreasing prevalence of hepatitis D virus infection. J Gastroenterol Hepatol (1997) 0.75
Autoimmune hepatitis associated with the antiphospholipid syndrome. Eur J Gastroenterol Hepatol (2001) 0.75
Late abdominal wall inflammatory mass mimicking drain site recurrence after rectal cancer surgery. Hippokratia (2012) 0.75
Proliferative activity in colonic adenomas as a predictor of metachronous adenomas as assessed by proliferating cell nuclear antigen immunohistochemistry. Am J Gastroenterol (1995) 0.75
Size of the speciality. Scand J Gastroenterol Suppl (1989) 0.75
HBeAg-negative hepatitis B in a previously thalassemic patient during immunosuppressive therapy for chronic GVHD. Bone Marrow Transplant (1998) 0.75
The precore sequence of hepatitis B virus is required for nuclear localization of the core protein. Hepatology (1997) 0.75
Primary liver cancer and its relationship to chronic infection with the hepatitis B virus. Springer Semin Immunopathol (1981) 0.75
Acute rhabdomyolysis following quail consumption. Ann Saudi Med (2007) 0.75
Fulminant hepatitis after flutamide treatment. J Hepatol (1994) 0.75
Retroperitoneal synovial sarcoma: a clinicopathological study of 6 cases. J BUON (2008) 0.75
Letter: Detection of HBAg by passive haemagglutination. Lancet (1974) 0.75
Delta antigen positive chronic liver disease in Greece: clinical aspects and natural course. Prog Clin Biol Res (1983) 0.75
Research as a part of education. Scand J Gastroenterol Suppl (1989) 0.75
Australia antigen in a family. Lancet (1970) 0.75
Deep jaundice in an adolescent. Postgrad Med J (2003) 0.75
Modern trends in the management of hepatocellular carcinoma. Drugs Exp Clin Res (1986) 0.75
Use of a monoclonal antibody in the detection of HBsAg in the liver by immunofluorescence. Dev Biol Stand (1983) 0.75
Hepatitis B vaccine in haemodialysis patients. Lancet (1984) 0.75
Serum hepatitis delta virus RNA in patients with delta hepatitis and in liver graft recipients. J Hepatol (1990) 0.75